The End­points 11; blue­bird's $3M gene ther­a­py; Bio­gen tout new neu­ro da­ta; Harsh re­views for can­cer drugs; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Read­ing about John Car­roll’s pick of biotech’s most promis­ing star­tups has be­come a trea­sured tra­di­tion. If you ever get cu­ri­ous about pre­vi­ous class­es of the End­points 11, you can find all of them (plus a num­ber of our oth­er reg­u­lar spe­cials) here.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.